Solid Dosage
GEA designs, produces and delivers innovative, integrated solutions for every stage of the manufacturing process of anti-diabetic drugs
With diabetes and the global anti-diabetes drug market on the rise, demand for GEA technologies for the production of these life-saving drugs is already high and set to increase, particularly in new markets and emerging economies
It is estimated that approximately 6.4% of the adult population worldwide has diabetes, leading to a huge demand for oral anti-diabetes drugs. To be able to cater for this demand, high-volume or mass production of these medicines is a fundamental requirement. It enables companies to produce goods faster and reduce the overall per unit production cost, allowing them to make anti-diabetes medications available to less-developed countries.
GEA has been instrumental in designing, producing and delivering innovative, integrated solutions for every stage of the manufacturing process: from materials handling to tablet coating, automation and monitoring. We continue to support this high-volume batch-based production with ongoing improvements and innovative developments.
One example is our range of double-sided tablet presses to accommodate the fact that many oral anti-diabetes medicines are bilayer combination drugs, consisting of two separate layers for each API.
Another trend that we have observed is the move towards continuous manufacturing (CM). Providing increased yields, lower utility consumption and reduced waste, CM meets the industry’s demands for improved production economics and increased manufacturing flexibility.
Focusing on quality during the whole product lifecycle and decreasing any associated risks, GEA is helping its customers to develop, evaluate and optimize continuous processing techniques to enable them to bring new products to market faster and cheaper.
Visualizzazione di 4 su 25
Ci occupiamo di integrazione di sistemi, e per farlo integriamo i prodotti software forniti dai leader di mercato con le conoscenze che abbiamo acquisito nel campo della tecnologia di processo e dell'ingegneria degli impianti.
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
La riduzione degli sprechi è importante per GEA e, sfruttando le potenzialità della tecnologia di liofilizzazione, possiamo trasformare le eccedenze alimentari in prodotti di valore e di lunga durata, contribuendo a ridurre gli sprechi, a prolungare la durata di conservazione e a creare maggiore resilienza nel sistema di approvvigionamento alimentare per le generazioni a venire.
Quando il produttore alimentare sudcoreano Pulmuone, attento alle tematiche ambientali, ha proposto a GEA di sviluppare una versione moderna dei tradizionali noodle freddi (naengmyeon), gli esperti di R&S di GEA si sono dimostrati pronti a cogliere la sfida. Hanno contribuito a sviluppare quello che oggi è un successo commerciale, prodotto con meno acqua ed elettricità rispetto ai metodi precedenti. Il risultato è anche fedele alle origini tradizionali del piatto e ai principi salutistici, di benessere e di sostenibilità di Pulmuone.